Esperion Therapeutics, Inc.
ESPREsperion Therapeutics, Inc. (ESPR) is a pharmaceutical company focused on developing and commercializing oral lipid-lowering medicines to treat patients with high cholesterol and related cardiovascular conditions. Founded in 2008, the company specializes in therapies targeting elevated LDL cholesterol through innovative oral agents, aiming to provide additional options for patients who require more effective lipid management.
Company News
Esperion announced that its partner Otsuka launched NEXLETOL in Japan, receiving a $90 million payment for the cardiovascular prevention drug's national health insurance price listing and market entry.
HLS Therapeutics received Health Canada approval to market NILEMDO® for reducing LDL-Cholesterol in Canadians at risk of cardiovascular disease, with commercial launch expected in Q2 2026.
Esperion announced the appointment of John Harlow as Chief Commercial Officer, bringing over two decades of pharmaceutical leadership experience to drive commercial strategies and global expansion of cardiovascular risk reduction therapies.
Esperion will present two research analyses at the AHA Scientific Sessions in New Orleans, focusing on bempedoic acid's impact on LDL cholesterol and cardiovascular events, including a monotherapy analysis and a study on venous thromboembolism.
Esperion Therapeutics plans to raise approximately $75 million through a public offering of 30 million shares at $2.50 per share, with underwriters having an option to purchase an additional 4.5 million shares.
